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ABSTRACT
The use of biochemical markers for predicting preterm birth has a potential advantage because it provides 
direct evidence of changes in the extracellular matrix of the surface between fetal membranes and the de-
cidual tissue (1,12). Fetal fibronectin (fFN) is a protein that is produced during pregnancy and acts as a bi-
ological glue which keeps the amniotic sac attached to the endometrium.  fFN can be found in cervico-vag-
inal secretions up to 22 weeks and later in the last trimester (7). The purpose of this study is to determine 
the level of fFN in cervical mucus as a specific indicator of preterm birth in pregnant women with clinical 
symptoms. The study was attended by 90 women divided into two groups. The first group of pregnant wom-
en were at term gestation 24-34 weeks with clinical symptoms of PB and the second group – with normal 
pregnancy. Full Term Test was conducted in all women. The results were statistically processed using SPSS 
v.17. The presence of symptoms of preterm labor showed difference in the percentage of positive results of 
the fFN test (p <0.05), women with clinical symptoms had a higher percentage of positive tests. When con-
ducting the Full Term pregnancy test with positive results in the highest percentage were women with overt 
clinical PB, Roma and those with second and third birth. Furthermore, for pregnant women with a positive 
test result with children mainly born at 35 weeks, the newborns weighed an average of 2, 550.1 g, which ex-
plicitly includes them in the premature population.
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INTRODUCTION
fFN is a high-molecular adhesive extracellular 
matrix glycoprotein. In the embryonic period, it is 
produced by the cells of cytotrophoblast (2). fFN is 
produced during pregnancy and acts as a biological 
glue by holding the amniotic sac attached to the 
endometrium (uterine lining). fFN can be found in 
cervico-vaginal secretions up to 22 weeks and later 
at the end of the last trimester (1 to 3 weeks before 
birth). fFN is usually missing in the mucus between 
24 and 34 weeks (5 ½ to 8 ½ months) (3,4,10).
The test usually takes place between 24 and 34 
weeks. The presence of fFN during these weeks, along 
with symptoms of labor, suggests that the „glue“ may 
decay and there is early detection of possible preterm 
labor (8,11).
The presence of fFN in the vagina of a pregnant 
woman up to 22 weeks is normal. In a normal 
pregnancy, between 22 weeks and 35 weeks, fFN 
should not be found in the cervico-vaginal secretions 
(6). Its presence is a highly informative biological 
marker for a risk of PB. Monoclonal antibody FDC-6 
was used in the test, which specifically recognizes the 
III-CS region of the fetal isoform of fibronectin (5,9).
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Fig. 1. Result of Full term test
Fig. 2. Results of Full term test according 
to the ethnicity of the mothers
Fig. 3. Results of Full term test in the order  
of birth of mothers
The purpose of this study is to determine the 
level of fFN in cervical mucus as a specific indicator 
of PB in pregnant women with clinical symptoms.
MATERIAL AND METHODS
In a prospective study conducted in the ma-
ternity ward of the University Hospital „St. Anna“–
Varna in the period August 2012 – August 2013, two 
main groups of pregnant women were included. The 
1-st group included 60 women with a pregnancy term 
24-34 weeks and clinical symptoms of PB. The 2-nd 
(control) group included 30 pregnant women with 
normal (physiologically) ongoing pregnancy. Both 
groups took the Full Term test. The test detects lev-
els of fFN ≥ 0.050 μg/mL. The result are ready in 10 
minutes, including the taking of secretion. Evidence 
of a negative test result: absence of fFN in women 
with no symptoms gives a 99% confidence that in the 
next 10-14 days PB will start; only 1% of women with 
negative results between 22 weeks and 24 weeks will 
give birth before 28 weeks. The negative result helps 
reduce unnecessary hospitalization and unnecessary 
use of medication. Indications of a positive test re-
sult: pregnant women with signs of labor and a posi-
tive test have a 40% chance to give birth premature-
ly; pregnant women without signs of labor and a pos-
itive test between weeks 22 and 24 weeks are 60 times 
more likely to give birth in the next 4 weeks. The pos-
itive result allows the doctor to take steps to delay the 
birth, as well as to use corticosteroids for lung matu-
ration and thus to improve the outcome of PB and re-
duce health risks to infants.
To process the results the statistical program 
SPSS v. 17 was used. Dispersion, correlation and 
comparative analysis was applied to prove the 
intended objective.
RESULTS
The results of the test for fFN from 90 mothers 
were positive for 33.30%, meaning high risk of PB 
(Fig. 1).
The presence of symptoms of preterm labor 
showed difference in the percentage of positive results 
of the fFN test (p <0.05) and women with clinical 
symptoms had a higher percentage of positive tests. 
In terms of ethnicity, we can say that with 
the exception of Roma ethnicity, where positive 
tests constitute approximately half of the group, in 
other mothers the percentage of positive tests is 
approximately one quarter of the respective group 
(Fig. 2).
With regard to the number of births and fFN 
test results we can say that it keeps the same pattern 
as in pregnancy. Again, approximately ¼ of mothers 
with a first and third birth give positive test results, 
while mothers, who give birth to a second child have 
positive results in one third of cases (Fig. 3).
From the viewpoint of the gestational age of 
the infant there was a significant difference between 
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Fig. 4. Results of Full term test and an average gestational 
age of the newborn
Fig. 5. Results of Full term test and the average birth 
weight
the mean age of the negative and positive results (p 
<0.001) and the age of the newborns with a negative 
result is higher than that of the ones with a positive 
result (Fig. 4).
The weight of the newborns also showed a 
significant difference in the two results of the fFN 
test (p <0.001), babies with positive results having a 
relatively lower weight than the infants with normal 
birth (Fig. 5).
It was proven by correlation analysis that there 
is an extremely strong proportional correlation (r 
= 0,97; p <0,001) between the gestational age of the 
fetus and its weight in women who tested positive in 
the fFN test. 
DISCUSSION
There was no significant difference in the 
number of births for the positive results from the test 
between women with and without clinical symptoms 
at first birth. The latter showed approximately 2-fold 
lower levels of positive tests at first birth compared to 
the clinical pregnancy group (p <0.01). 
Birth weight in women with a negative result 
was approximately 400 g higher than that of children 
born to women with positive test results (p <0.001). 
However, children born to the second group of 
women were slightly above the weight limit for PB 
(about 2600 g). For the first group of women, the 
infants had predominantly normal birth weight 
(average weight of 3200 g). 
Difference was also observed in the gestational 
age of the fetus (p <0.001) –  women with positive test 
results and presence of clinical symptoms gave birth 
3 weeks earlier, which puts them in the group of PBs 
(average gestational age in women without symptoms 
was 38 weeks, and in women with symptoms - 35 
weeks gestation). 
CONCLUSIONS
In clinical practice we often encounter 
pregnant women with clinical symptoms of PB 
when you need to predict the onset of parturition 
and need assessment of the feasibility for the birth 
to be postponed or delayed until the most favorable 
gestational week for the survival of fetus. 
The application of rapid immunoassay tests 
from 24 to 34 weeks, enables us for a very short 
period of time - 10 to 15 minutes, to define high-risk 
mothers and take the necessary therapeutic measures 
to prevent PB. 
After conducting a Full Term pregnancy test 
with positive results in the highest percentage were 
women with overt clinical PB, Roma and second and 
third birth women. Furthermore, pregnant women 
with a positive test result mainly gave birth at 35 
weeks, with newborns weighing an average of 2,550.1 
g, which explicitly includes them in the premature 
birth population. 
The Full Term test has high sensitivity and 
specificity, which gives us reason to believe that the 
resulting positive and negative values are sufficient 
grounds to accept or reject the risk of occurrence of 
PB.
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